about
Thrombocytopenia in patients receiving oral anticoagulant therapy.Patient preference for needleless factor VIII reconstitution device: the Italian experienceEfficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and AlloantibodiesCyclam-cored dendrimers appended with four dendrons of two different types: intradendrimer energy transfer.Dietary interactions and INR variability: retrospective evaluation of patients couples on oral anticoagulant therapy.Role of hyperhomocystinemia in retinal vascular occlusive disease.Congenital hypodysfibrinogenemia and abruptio placentae in a woman with history of cerebral thrombosis.Central nervous system bleeding in patients with rare bleeding disorders.Iliac giant pseudotumour in a haemophiliac patient.Thrombosis in hemophiliacs with prothrombotic molecular defect.Genetic prothrombotic risk factors in women with unexplained pregnancy loss.Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population.Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controlsEvaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenonCorrelation between family history of hypertension and haemostatic disordersIncreased indexes of thrombin activation in advanced stages of hypertensionClinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive diseaseStudy of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapyEfficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon[Prothrombotic gene mutations in women with recurrent abortions and intrauterine fetal death]
P50
Q33344532-C4E939D7-2FD5-401F-8113-9612B4E94932Q34041899-A20CF357-20AB-411C-A4EF-9180BBA59B31Q42364688-C4D17E58-6B4F-4BFC-A3FD-85E395C5BE42Q43030051-145FE688-BCC2-4FE5-994A-EEF4555C20C2Q45024747-814AD75F-5AC7-435D-95C6-948C755F92EBQ45864388-AD08792E-C042-4C39-B5EC-7E13498E85E8Q45866676-D2B414D7-CC3B-4DC5-B087-9E01C60FB41FQ45869762-881FB06C-D8DF-49F5-9831-17DE1C9F24E2Q45876493-A5B103C1-7AB3-4D8F-ADFF-E720E5D77B50Q45885093-39D03B35-B351-45B0-BE0E-F3CB57DB2C21Q47859588-6BB6C7DF-2685-4DC0-A68D-0C5D610F95A4Q48357972-6FBAC93B-87EF-43F5-837D-463945B2BF18Q56342204-4120C818-EBE2-462B-90D4-8C4E4DF9F1BCQ73042966-EC292991-3A55-4966-9ABA-B3B1FC75B81BQ73794547-EB03B05D-75EF-4B87-B815-EAE1CD80D924Q74027357-F06390EA-1A02-46B1-A008-CAD0051083CCQ77406218-D912BAC6-64E2-4311-B96F-7423EEA876F8Q77946976-0B1554BE-655C-44EA-AAD8-8458D7EF3672Q78234601-215E488F-5E54-445D-A27D-F91803619CF5Q81231920-00A260E9-3445-43D7-A3C9-1E1121A2E332
P50
description
Wissenschaftler
@de
scientist
@en
wetenschapper
@nl
name
Gianluca Sottilotta
@ast
Gianluca Sottilotta
@de
Gianluca Sottilotta
@en
Gianluca Sottilotta
@es
Gianluca Sottilotta
@nl
Gianluca Sottilotta
@sl
type
label
Gianluca Sottilotta
@ast
Gianluca Sottilotta
@de
Gianluca Sottilotta
@en
Gianluca Sottilotta
@es
Gianluca Sottilotta
@nl
Gianluca Sottilotta
@sl
prefLabel
Gianluca Sottilotta
@ast
Gianluca Sottilotta
@de
Gianluca Sottilotta
@en
Gianluca Sottilotta
@es
Gianluca Sottilotta
@nl
Gianluca Sottilotta
@sl
P106
P21
P31
P496
0000-0001-8833-1514